Susquehanna International Group’s Ovid Therapeutics OVID Stock Holding History

Susquehanna International Group’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$143K	Buy	64,200 +52,200	+435%	+$93.3K	﹤0.01%	12064
2025 Q4	$19.6K	Sell	12,000 -46,100	-79%	-$71K	﹤0.01%	11967
2025 Q3	$75.5K	Buy	+58,100	New	+$50.4K	﹤0.01%	11708
2022 Q3	–	Sell	-11,300	Closed	-$24K	–	13874
2022 Q2	$24K	Sell	11,300 -14,000	-55%	-$33.8K	﹤0.01%	12314
2022 Q1	$79K	Sell	25,300 -92,900	-79%	-$292K	﹤0.01%	12063
2021 Q4	$379K	Sell	118,200 -79,900	-40%	-$274K	﹤0.01%	9920
2021 Q3	$666K	Sell	198,100 -6,900	-3%	-$25.2K	﹤0.01%	8646
2021 Q2	$802K	Buy	205,000 +22,300	+12%	+$88K	﹤0.01%	8367
2021 Q1	$734K	Buy	182,700 +172,700	+1,727%	+$574K	﹤0.01%	8536
2020 Q4	$23K	Sell	10,000 -36,100	-78%	-$168K	﹤0.01%	10870
2020 Q3	$265K	Sell	46,100 -23,400	-34%	-$157K	﹤0.01%	8960
2020 Q2	$512K	Buy	+69,500	New	+$325K	﹤0.01%	7308

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Susquehanna International Group's OVID Position: Q1 2026 in Review

Susquehanna International Group increased its Ovid Therapeutics (OVID) stake by 470% in Q1 2026, buying an estimated $2.87M and bringing the position to 1,947,594 shares worth $4.32M. The position accounts for ﹤0.01% of the portfolio, ranked #4506.

Susquehanna International Group first reported a position in OVID in Q4 2019 and has held it in 20 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Susquehanna International Group held 1,947,594 shares of Ovid Therapeutics worth $4.32M as of Q1 2026.
Susquehanna International Group bought 1,605,854 Ovid Therapeutics shares in Q1 2026, an estimated $2.87M.
Ovid Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4506 holding.
Susquehanna International Group first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 20 quarters since.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.